Table 4.
Treatments and outcomes.
| Studies without a Comparator | Studies with a Comparator | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shin 2017 [10] |
Ravi 2018 [11] |
Jurczyszyn 2019 [13] |
Caulier 2021 [16] |
Bao 2022 [17] |
Jurczyszyn 2016 [19] | Nakaya 2020 [21] |
Pál 2020 [14] |
||||
| n | 32 | 212 | 52 | 214 | 258 | 173 | 916 | 26 | 2277 | 16 | 296 |
| Age studied (years) | ≤40 | ≤50 | ≤30 | ≤40 | <50 | 21–40 | 41–60 | <40 | All | ≤40 | >40 |
| Year of diagnosis | 2000–2015 | 2005–2015 | 2006–2016 | 2000–2015 | 1992–2019 | 2000–2015 | 1998–2018 | 2006–2015 | |||
| Induction treatments (%) | Novel agents, unspecified | ||||||||||
| PI based | 10 | 45 b | 41 | 30 | 22 | NA | NA | NA | NA | 6 | NA |
| IMID based | 37 | 32 b | 24 | 1 | 10 | NA | NA | NA | NA | 13 | NA |
| PI + IMIDs | 40 a | 15 b | 21 | 37 | 27 | NA | NA | NA | NA | 69 | NA |
| Other (chemotherapy, melphalan, dexamethasone only) | 13 | 6 b | 15 | 26 | 41 | NA | NA | NA | NA | 13 | NA |
| Radiotherapy only | NA | NA | NA | 6 | NA | NA | NA | NA | NA | NA | NA |
| Transplant | |||||||||||
| ASCT (%) 1st line | 62 | NA | 62 | NA | NA | NA | NA | NA | NA | 88 | NA |
| ASCT (%)—at any stage | 79 | 52 | NA | 93 | 87 | 11 | 89 | 39 | NA | NA | NA |
| Allo-SCT (%) | 0 | NA | 3 | 25 | 5 c | NA | NA | 42 d | NA | NA | NA |
| Survival data | |||||||||||
| Median follow-up (months) | 64 | 69.6 | 86 | 76 | 93.6 | 51 | 78 | NA | NA | ||
| Median OS (months) | 61 | NA | 166 | 175 | 112.8 | NA | NA | NA | NA | NA | NA |
| 5-years OS (%) | 54 | 70 | 77 | 84 | 86 (NHBP) 66 (NHWP) |
83 | 67 p < 0.001 |
71 | 56 | 83 | 53 |
| Median PFS (months) | 16 | NA | NA | 41 | 38.4 (NHWP), 70.8 (NHPB) |
NA | NA | NA | NA | NA | NA |
| 5-years PFS (%) | 14 | 28 | NA | NA | NA | NA | NA | NA | NA | 48 | 35 |
a VAD +/− VTD; b numbers not adding to 100% due to missing data; c ASCT followed by Allo-SCT d 23% with a combination of ASCT and allo-SCT + 19% allo-SCT. ASCT: autologous stem cell transplant; Allo-SCT: allogeneic stem cell transplant; NHBP: non-hispanic black people; NHWP: non-hispanic white people; OS: overall survival; PFS: progression-free survival.